Mode
Text Size
Log in / Sign up
N/A Completed N=29 Randomized Health Services Research

Remote Pulmonary Function Testing and Nurse Coaching in ALS

ALS
Source: ClinicalTrials.gov NCT04490148 ↗
Enrolled (actual)
29
Serious AEs
24.1%
Results posted
Jun 2024
Primary outcomePrimary: Date of Identification of Noninvasive Ventilation (NIV) Need From rPFT Monitoring — 176 days after enrollment

Summary

Comparison of respiratory outcomes in patients receiving telemedicine-guided remote pulmonary function testing (rPFT) with or without the additional support of nurse coaching. This is a randomized controlled study which assesses the effects rPFT and coaching on respiratory outcomes and quality of life.

Outcome Measures

OutcomeResultp-value
PRIMARY
Date of Identification of Noninvasive Ventilation (NIV) Need From rPFT Monitoring
176
PRIMARY
Date of Identification of NIV Need From Standard PFT Monitoring
259
PRIMARY
Self-efficacy for Managing Medications and Treatments
-.238; .474
PRIMARY
Self-efficacy for Managing Social Interactions
-.041; -.181
PRIMARY
Self-efficacy for Managing Symptoms
-.279; -.255
SECONDARY
Dyspnea Characteristics
.029; .272
SECONDARY
Respiratory-related Symptoms
11.4; 7.6
SECONDARY
rPFT Adherence
82.2
SECONDARY
Dyspnea Functional Limitations
-.022; -.255
SECONDARY
Sleep Related Impairment
.095; .140

Eligibility Criteria

Inclusion Criteria

Patients:

  • Possess a diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [Brooks2000].
  • Be 18 years of age or older.
  • Have a caregiver available to participate in the study
  • Symptom onset within the last three years.
  • Have a computer and home internet service sufficient for engaging in telemedicine sessions.
  • Have a second device capable of downloading the spirometer application from an app store (Android- or iOS-based smartphone or tablet).

Caregivers:

  • Be 18 years of age or older, of either gender.
  • Be able and willing to provide informed consent.

Exclusion Criteria

Patients:

  • Use of NIV or diaphragm pacer at time of obtaining informed consent.
  • FVC ≤50% predicted or MIP > -60 cm of water.
  • ALS Functional Rating Scale (ALSFRS-R) [Cedarbaum1999] score on day of screening of ≥2 on items for speech, swallowing, and salivation. These items are indicators of bulbar dysfunction, which limits the reliability of PFT administration.
  • Cognitive impairment, as judged by the ALS clinic neurologist, that prevents participation in the study.

Caregivers: None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04490148). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search